Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djx187
Abstract: Conventional cancer clinical trials can be slow and costly, often produce results with limited external validity, and are difficult for patients to participate in. Recent technological advances and a dynamic policy landscape in the United…
read more here.
Keywords:
evidence generation;
real world;
oncology;
clinical trials ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Orphanet Journal of Rare Diseases"
DOI: 10.1186/s13023-020-01370-3
Abstract: Background Many treatments developed for rare diseases will have an Orphan Medicinal Product (OMP) designation, indicating that they are likely to deliver benefit in an area of high unmet need. Their approval may be based…
read more here.
Keywords:
evidence generation;
specialised treatments;
rare diseases;
evidence ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2017-0073
Abstract: It is common for pharmaceutical companies to consider evidence generation as the responsibility of individual departments (e.g., clinical development, medical affairs and health economics and outcomes research). This typically means that evidence is generated in…
read more here.
Keywords:
evidence generation;
evidence;
developing integrated;
strategy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2022.773629
Abstract: Gene therapies (GTs) are considered to be a paradigm-shifting class of treatments with the potential to treat previously incurable diseases or those with significant unmet treatment needs. However, considerable challenges remain in their health technology…
read more here.
Keywords:
health technology;
evidence generation;
analysis;
evidence ... See more keywords